Daré Bioscience to Present at the 35th Annual Roth Conference

On March 1, 2023 Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, reported that Sabrina Martucci Johnson, the company’s President and CEO, will present at the 35th Annual Roth Conference, being held March 12-14, 2023 in Laguna Niguel, CA (Press release, Daré Bioscience, MAR 1, 2023, View Source [SID1234628007]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ms. Johnson’s presentation is scheduled for Tuesday, March 14th at 8:30 a.m. PDT. A live webcast of the presentation will be available at View Source and under "Presentations, Events & Webcasts" in the Investors section of the company’s website at View Source The webcast will be archived in the same section of the Company’s website and available for replay until March 28, 2023.

Members of the company’s management team will be available for one-on-one meetings. Investors attending the conference who are interested in meeting with Daré management may request a meeting by contacting their Roth sales representative.

Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference

On March 1, 2023 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, reported that it will webcast its presentation at the Cowen 43rd Annual Health Care Conference at 9:50 a.m. ET on Wednesday, March 8, 2023 (Press release, Sana Biotechnology, MAR 1, 2023, https://ir.sana.com/news-releases/news-release-details/sana-biotechnology-present-cowen-43rd-annual-health-care [SID1234628006]). The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be accessible on the Investor Relations page of Sana’s website at View Source A replay of the presentation will be available at the same location for 30 days following the conference.

ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen’s ADC Technology in the Development of Novel Targeted Conditioning Agents

On March 1, 2023 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs), reported a global, multi-target license and option agreement whereby it granted Vertex Pharmaceuticals (Vertex) (NYSE: VRTX) rights to conduct research using ImmunoGen’s ADC technology to discover novel targeted conditioning agents for use with gene editing (Press release, ImmunoGen, MAR 1, 2023, View Source [SID1234628005]). Following the research period for each target, Vertex will have the option to obtain a worldwide, exclusive license to research, develop, and commercialize conditioning agents employing ImmunoGen’s technology for that target. ImmunoGen will retain full rights to the ADC technology for all targets not covered by the Vertex license.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of the agreement, Vertex will pay ImmunoGen an upfront payment of $15 million. ImmunoGen is eligible to receive up to $337 million in option exercise fees and development and commercial milestone payments per target. ImmunoGen will be eligible to receive tiered royalties as a percentage of worldwide commercial sales of novel licensed targeted conditioning agents by Vertex. Vertex is responsible for all research, development, and commercialization and related costs.

"Given Vertex’s extensive experience discovering and developing transformative medicines for patients with serious diseases, we are thrilled they have chosen to explore ImmunoGen’s technology to develop ADCs for transplant conditioning in connection with gene editing," said Michael Vasconcelles, MD, ImmunoGen’s Executive Vice President, Research, Development, and Medical Affairs. "This agreement reflects our continued innovation in the ADC space and demonstrates the value of our technology platform and related intellectual property."

"We look forward to evaluating the potential of ImmunoGen’s technology to develop a gentler conditioning regimen for use with Vertex’s exagamglogene autotemcel (exa-cel), for the potential treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)," said Mike Cooke, PhD, SVP, Vertex Cell and Genetic Therapies.

CTI BioPharma to Present at the 43rd Annual Cowen Health Care Conference

On March 1, 2023 CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, reported that the management team will present a corporate overview at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023 at 10:30 a.m. ET (7:30 a.m. PT) (Press release, CTI BioPharma, MAR 1, 2023, View Source [SID1234628004]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A link to the live and archived webcast may be accessed on the CTI BioPharma website under the Investors & Media section: Events and Presentations.

Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

On March 1, 2023 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, reported that it received formal notice from The Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with Nasdaq’s minimum bid price for continued listing on the Nasdaq Global Select Market as set forth in Nasdaq Listing Rule 5450(a)(1) ("Min Bid Price Rule") (Press release, Aprea, MAR 1, 2023, View Source [SID1234628003]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited about regaining compliance and we believe our recent financing, which was supported by quality institutions, has strengthened our balance sheet and enabled the Company to continue developing its clinical asset, ATRN-119, and its pre-clinical asset ATRN-W1051" said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea Therapeutics.